[go: up one dir, main page]

CN1449380A - 作为选择性5－羟色胺再摄取抑制剂的苯氧基苄胺衍生物 - Google Patents

作为选择性5－羟色胺再摄取抑制剂的苯氧基苄胺衍生物 Download PDF

Info

Publication number
CN1449380A
CN1449380A CN01814846A CN01814846A CN1449380A CN 1449380 A CN1449380 A CN 1449380A CN 01814846 A CN01814846 A CN 01814846A CN 01814846 A CN01814846 A CN 01814846A CN 1449380 A CN1449380 A CN 1449380A
Authority
CN
China
Prior art keywords
compound
methyl
formula
compounds
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01814846A
Other languages
English (en)
Chinese (zh)
Inventor
M·D·亚当
M·D·安德鲁斯
M·L·埃里奥特
G·E·吉默
D·赫普沃斯
H·R·小霍华德
D·S·米德尔顿
A·斯托比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0021593A external-priority patent/GB0021593D0/en
Priority claimed from GB0107116A external-priority patent/GB0107116D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1449380A publication Critical patent/CN1449380A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN01814846A 2000-08-31 2001-08-22 作为选择性5－羟色胺再摄取抑制剂的苯氧基苄胺衍生物 Pending CN1449380A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0021593A GB0021593D0 (en) 2000-08-31 2000-08-31 Diphenyl ether compounds useful in therapy
GB0021593.9 2000-08-31
GB0107116A GB0107116D0 (en) 2001-03-21 2001-03-21 Novel compounds
GB0107116.6 2001-03-21

Publications (1)

Publication Number Publication Date
CN1449380A true CN1449380A (zh) 2003-10-15

Family

ID=26244953

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01814846A Pending CN1449380A (zh) 2000-08-31 2001-08-22 作为选择性5－羟色胺再摄取抑制剂的苯氧基苄胺衍生物

Country Status (32)

Country Link
EP (1) EP1313701A1 (es)
JP (1) JP2004507523A (es)
KR (1) KR20030029889A (es)
CN (1) CN1449380A (es)
AP (1) AP2001002265A0 (es)
AR (1) AR031867A1 (es)
AU (1) AU2001278650A1 (es)
BG (1) BG107544A (es)
BR (1) BR0113610A (es)
CA (1) CA2420969A1 (es)
CZ (1) CZ2003467A3 (es)
DO (1) DOP2001000242A (es)
DZ (1) DZ3414A1 (es)
EA (1) EA200300206A1 (es)
EE (1) EE200300084A (es)
HN (1) HN2001000191A (es)
HR (1) HRP20030141A2 (es)
HU (1) HUP0303385A2 (es)
IL (1) IL154343A0 (es)
IS (1) IS6704A (es)
MA (1) MA26945A1 (es)
MX (1) MXPA03001848A (es)
NO (1) NO20030842L (es)
NZ (1) NZ523951A (es)
OA (1) OA12372A (es)
PA (1) PA8526701A1 (es)
PE (1) PE20020346A1 (es)
PL (1) PL360743A1 (es)
SK (1) SK2012003A3 (es)
TN (1) TNSN01131A1 (es)
UY (1) UY26924A1 (es)
WO (1) WO2002018333A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20020183306A1 (en) * 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
GB0318706D0 (en) * 2003-08-08 2003-09-10 Pfizer Ltd Selective serotonin reuptake inhibitors in the treatment of disease
KR100783255B1 (ko) 2004-02-13 2007-12-06 워너-램버트 캄파니 엘엘씨 안드로젠 수용체 조절제
JP2007532621A (ja) 2004-04-13 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレータ
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
CA2570047C (en) 2004-07-08 2010-09-28 Warner-Lambert Company Llc 4-cycloalkoxy benzonitriles as androgen modulators
CA2577448A1 (en) * 2004-08-18 2006-02-23 Warner-Lambert Company Llc Androgen modulators
BRPI0514675A (pt) * 2004-09-10 2008-06-17 Pfizer Prod Inc ligantes de éter difenìlico terapêuticos
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
WO2007010350A1 (en) * 2005-07-19 2007-01-25 Pfizer Products Inc. Synthesis of therapeutic diphenyl ethers
EP1943226A2 (en) 2005-10-13 2008-07-16 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
WO2008002820A2 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
US7767666B2 (en) 2006-06-29 2010-08-03 Janssen Pharmaceutica Nv Butyl and butynyl benzyl amine compounds
US20080045508A1 (en) * 2006-06-29 2008-02-21 Brett Allison Substituted aminomethyl benzamide compounds
US8642583B2 (en) 2008-10-30 2014-02-04 Janssen Pharmaceutica Nv Serotonin receptor modulators
WO2010059390A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Modulators of serotonin receptor
KR101043200B1 (ko) * 2010-11-08 2011-06-21 성시민 호흡용 공기탱크의 공기 충전장치
WO2012102721A1 (en) 2011-01-27 2012-08-02 Hewlett-Packard Development Company, L.P. A computing device to connect to a portable device
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
EP0714391A1 (en) * 1993-08-19 1996-06-05 Warner-Lambert Company Substituted 2(5h)furanone, 2(5h)thiophenone and 2(5h)pyrrolone derivatives, their preparation and their use as endothelin antagonists
CZ293595A3 (cs) * 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
EP1071648A2 (en) * 1998-03-13 2001-01-31 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
EE200100441A (et) * 1999-02-23 2002-12-16 Pfizer Products Inc. Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
GB0007884D0 (en) * 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy

Also Published As

Publication number Publication date
BR0113610A (pt) 2003-06-24
EA200300206A1 (ru) 2003-06-26
CA2420969A1 (en) 2002-03-07
SK2012003A3 (en) 2004-06-08
TNSN01131A1 (fr) 2005-11-10
MA26945A1 (fr) 2004-12-20
AP2001002265A0 (en) 2001-09-30
PL360743A1 (en) 2004-09-20
MXPA03001848A (es) 2003-06-04
EP1313701A1 (en) 2003-05-28
NZ523951A (en) 2004-09-24
NO20030842D0 (no) 2003-02-24
KR20030029889A (ko) 2003-04-16
WO2002018333A1 (en) 2002-03-07
OA12372A (en) 2006-04-17
JP2004507523A (ja) 2004-03-11
HUP0303385A2 (hu) 2004-03-01
PE20020346A1 (es) 2002-05-08
EE200300084A (et) 2005-02-15
CZ2003467A3 (cs) 2004-04-14
BG107544A (bg) 2003-10-31
NO20030842L (no) 2003-04-28
UY26924A1 (es) 2002-03-22
HN2001000191A (es) 2002-03-11
IS6704A (is) 2003-01-30
AR031867A1 (es) 2003-10-08
AU2001278650A1 (en) 2002-03-13
PA8526701A1 (es) 2003-07-28
DOP2001000242A (es) 2002-05-15
DZ3414A1 (fr) 2002-03-07
HRP20030141A2 (en) 2003-04-30
IL154343A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
CN1449380A (zh) 作为选择性5－羟色胺再摄取抑制剂的苯氧基苄胺衍生物
CN1204138C (zh) 吡唑并[4,3－d]嘧啶衍生物
CN1221524C (zh) 治疗用的二苯基醚化合物
CN1066719C (zh) 对中枢神经系统具有药理活性的化合物的制备方法
CN1158256C (zh) 吡咯烷衍生物-ccr-3受体拮抗剂
CN1285580C (zh) 嘧啶化合物
CN1243723C (zh) 作为fsad的nep抑制剂的n－苯丙基环戊基取代的戊二酰胺衍生物
CN1227237C (zh) 作为五羟色胺5－ht2受体拮抗剂的哌嗪基吡嗪化合物
CN1263755C (zh) 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
CN1745074A (zh) 5－ht受体配体及其用途
CN1665789A (zh) 二氨基嘧啶酰胺衍生物
CN1656075A (zh) 喹啉衍生物和其作为5－ht6配体的用途
CN1422273A (zh) 1,5－二取代－3,4－二氢－1H－嘧啶并[4,5－d]嘧啶二酮化合物和其在治疗CSBP/p38激酶介导的疾病中的用途
CN1390196A (zh) 具有药理活性的新的二羧酸衍生物
CN1950089A (zh) 吗啉化合物
CN1608050A (zh) 哌嗪衍生物
CN1768040A (zh) 作为akt(蛋白激酶b)抑制剂的异喹啉－5－磺酸酰胺
CN1053658C (zh) 氨基芪唑衍生物和药
CN1329614A (zh) 稠合的哒嗪衍生物、它们的制备方法和用途
CN1656072A (zh) 作为5－羟色胺再摄取抑制剂的苯基杂环基醚衍生物
CN1922156A (zh) 作为钠通道阻断剂的取代的三唑
CN101068817A (zh) 新型吡啶并噻吩并嘧啶衍生物
HK1055940A (en) Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
CN1413112A (zh) 含有稠合哒嗪衍生物的滴鼻剂
CN1169141A (zh) 新的胺衍生物，制备它们的方法和它们作为抗心律失常药的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1055940

Country of ref document: HK